Alexium International Group Ltd (ASX: AJX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Alexium International Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Alexium International Group Ltd (ASX: AJX)
Latest News
⏸️ Investing
10 S&P/ASX 300 growth shares with big potential
⏸️ Investing
5 ASX stocks that have gained more than 300% in the past year
⏸️ Investing
Why these 4 ASX stocks are soaring today
⏸️ Investing
5 stocks sinking on the ASX today
⏸️ Investing
4 ASX stocks hammered down today
⏸️ Investing
4 stocks soaring on the ASX today
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 26 Mar 2004 | $0.0200 | 100.00% | Interim | 15 Apr 2004 |
AJX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Alexium International Group Ltd
Alexium International Group Ltd. engages in the provision of developing chemical solutions. It is involved in the development and licensing of its proprietary flame retardant phase change material, chemicals and reactive surface treatment technologies. Its products include Alexicool, Alexiflam FR and Alexiflam NF. The company was founded on May 30, 1994 and is headquartered in Greer, SC.
AJX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 19 Nov 2026 | $0.01 | $0.00 | 0.00% | 1,185,853 | $0.01 | $0.01 | $0.01 |
| 11 Nov 2026 | $0.01 | $0.00 | 0.00% | 597,821 | $0.01 | $0.01 | $0.01 |
| 10 Nov 2026 | $0.00 | $0.00 | 0.00% | 60,000 | $0.00 | $0.00 | $0.00 |
| 29 Oct 2026 | $0.01 | $0.00 | 0.00% | 16,715 | $0.01 | $0.01 | $0.01 |
| 27 Oct 2026 | $0.01 | $0.00 | 0.00% | 6,050 | $0.01 | $0.01 | $0.01 |
| 26 Oct 2026 | $0.01 | $0.00 | 0.00% | 23,589 | $0.01 | $0.01 | $0.01 |
| 23 Oct 2026 | $0.01 | $0.00 | 0.00% | 50,000 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Nov 2026 | William (Billy) Blackburn | Issued | 8,338,857 | $50,033 |
Issue of securities. Estimated value per share: $0.006
|
| 09 Oct 2026 | William (Billy) Blackburn | Expiry | 6,712,233 | $40,273 |
As advised by the company. 6,712,233 rights lapsed; 92,354,851 Share Appreciation Rights
|
| 22 Sep 2026 | Simon Moore | Issued | 12,330,616 | $81,382 |
Director remuneration. as per announcement 25-09-26
|
| 22 Sep 2026 | James Williamson | Issued | 6,165,315 | $40,691 |
Director remuneration.
|
| 22 Sep 2026 | Paul Stenson | Issued | 4,007,454 | $26,449 |
Director remuneration.
|
| 22 Sep 2026 | Martyn Strickland | Issued | 6,165,315 | $40,691 |
Director remuneration. As per announcement 25-09-26
|
| 22 Sep 2026 | T Lane | Issued | 11,172,480 | $73,738 |
Director remuneration.
|
| 28 Jan 2026 | Martyn Strickland | Issued | 809,044,333 | $4,854,265 |
Rights issue.
|
| 28 Jan 2026 | Simon Moore | Issued | 809,044,333 | $4,854,265 |
Rights issue.
|
| 28 Jan 2026 | William (Billy) Blackburn | Issued | 16,659,830 | $99,958 |
Rights issue.
|
| 28 Jan 2026 | Paul Stenson | Issued | 6,195,833 | $37,174 |
Rights issue.
|
| 28 Jan 2026 | T Lane | Issued | 10,127,605 | $60,765 |
Rights issue.
|
| 28 Jan 2026 | James Williamson | Issued | 136,981,856 | $821,891 |
Rights issue.
|
| 17 Dec 2025 | Simon Moore | Issued | 9,715,591 | $68,009 |
Director remuneration. As per announcement on 17-12-2025
|
| 17 Dec 2025 | Martyn Strickland | Issued | 4,857,803 | $34,004 |
Director remuneration. As per announcement 17/12/2025
|
| 17 Dec 2025 | James Williamson | Issued | 8,373,970 | $58,617 |
Director remuneration.
|
| 17 Dec 2025 | Paul Stenson | Issued | 3,157,570 | $22,102 |
Director remuneration.
|
| 17 Dec 2025 | T Lane | Issued | 3,157,570 | $22,102 |
Director remuneration.
|
| 12 Dec 2025 | William (Billy) Blackburn | Issued | 66,491,935 | $465,443 |
Issue of securities. 99,067,084 rights
|
| 12 Dec 2025 | T Lane | Issued | 8,063,233 | $56,442 |
Issue of securities. 8,063,233 Share Appreciation Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Simon Colinton Moore | Non-Executive DirectorInterim Chairman | Feb 2020 |
Mr Moore is the Senior Partner of the investment firm, Colinton Capital Partners. Prior to establishing Colinton Capital Partners in 2017, Mr Moore was a Global Partner of The Carlyle Group having established their operation in Australia in 2005. In his time at The Carlyle Group, he oversaw the Firm's investments in and served on the Boards of Directors of Coates Hire, Healthscope and QUBE. He is currently a member of the Risk Committee.
|
| Dr Paul Henry Stenson | Non-Executive Director | Jun 2020 |
Dr Stenson has a career with the research, development, manufacture, and commercialization of new materials in the fields of coatings, adhesives, nonwovens, and pharmaceuticals. Dr Stenson was President and CEO of StanChem Inc. from January 2018 to April 2024. StanChem Inc. is comprised of two companies - StanChem Polymers which is a manufacturer of water-based polymers for the coatings and adhesives industries, and Albi Protective Coatings which focuses on the specialty sector of fire protective intumescent paints and specialty high-performance industrial coatings. Prior to joining StanChem in 2017, he worked as a global technology director at Axalta Coating Systems. Between 2011 and 2016, Dr Stenson was the executive vice president of technology and product development at Ahlstrom for nonwoven and specialty high-performance paper products. Prior to joining Ahlstrom, Dr Stenson was the vice president of technology for industrial and packaging coatings at Valspar based in Minneapolis and Zurich, Switzerland from 1993 until 2011. Dr Stenson is also the chairman of TopChem Pharmaceuticals (Ireland) which is a manufacturer of active pharmaceutical ingredients. He is the chair of the Risk Committee.
|
| Mr William (Billy) Timothy Blackburn | Chief Executive OfficerManaging Director | Sep 2022 |
Mr Blackburn has over 25 years of experience in general management. He founded Emes, LLC, a technology-based specialty chemical business. Emes had a business model focused on high-purity chemical production paired with recycling in the pharmaceutical and consumer healthcare markets. Mr. Blackburn sold the business to Nova Molecular and then joined their executive team to lead further commercial growth of the merged organizations. More recently, Mr. Blackburn was the Vice President of Giant Cement Holdings Inc., and executive manager of its subsidiary, Giant Resource Recovery (GRR). He also raised capital for the GRR business to modernize its plants for sustained growth.
|
| Mr T Randall Lane | Non-Executive Director | Jul 2024 |
Mr Lane has had a career in research, manufacturing, start-ups and product commercialization including 25 years of senior management positions in the chemical and medical device industries. Specifically, he has served as CEO/CSO at CAVU group, comprised of Microtek, American Thermal Instruments and Latent Heat Solutions. Mr. Lane has also served on several Boards in the private sector.
|
| Mr Martyn Strickland | Non-Executive Director | Jul 2024 |
Mr Strickland prior to joining Colinton Capital Partners, was a Senior Partner at Deloitte, where he led their middle-market strategy and the Operational Restructuring and CRO services divisions within the Financial Advisory business. Prior to Deloitte, Martyn joined KordaMentha as Managing Director to establish their 333 Consulting business focusing on company side turnaround, restructuring and growth. Prior to 333, Martyn was Principal with A.T. Kearney and an Operating Executive with Cadbury Schweppes. Mr Strickland is a member of the Risk Committee.
|
| Mr James Williamson | Interim Non-Executive Director | Nov 2024 |
Mr Williamson has over 30 years of experience in financial markets and is the Co-Founder and Chief Investment Officer of Wentworth Williamson Management. Founded in 2013, Wentworth Williamson Management is a private Australian-based value fund manager with both equity and private credit funds. Prior to Wentworth Williamson, Mr Williamson worked for Allan Gray Australia and prior to that he was Portfolio Manager of the Investec Australian Equity Fund.
|
| Ms Sandra McIntosh | Company Secretary | Mar 2026 |
-
|
| Sandra McIntosh | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Colinton Capital Partners Pty Ltd <Colinton Cp Fund 1 (A) A/C> | 1,061,013,112 | 33.92% |
| Colinton Capital Partners Pty Ltd | 580,289,944 | 18.55% |
| Microtek Holdings Inc | 361,717,485 | 11.56% |
| Sandhurst Trustees Ltd <Wentworth Williamson A/C> | 306,984,033 | 9.81% |
| Dr Stuart Lloyd Phillips & Mrs Fiona Jane Phillips <Sl & Fj Phillips Pens F A/C> | 186,576,008 | 5.97% |
| N & G Td Proprietary Limited <N & G Td Super Fund A/C> | 46,000,000 | 1.47% |
| Dr Elyse Jane Phillips | 39,999,999 | 1.28% |
| Dr Paul Stenson | 30,331,404 | 0.97% |
| William T Blackburn Jr | 28,659,830 | 0.92% |
| Randall Lane | 21,184,918 | 0.68% |
| Mr Michael Joseph Duhamel & Ms Kathleen Mary Beaman <Duhamel & Beaman S/F A/C> | 21,000,000 | 0.67% |
| Bnp Paribas Nominees Pty Ltd <Clearstream> | 18,821,779 | 0.60% |
| Mrs Sandra Kaye Conti | 12,920,000 | 0.41% |
| Mr Joseph John Hill | 12,000,000 | 0.38% |
| Rosheen Garnon | 11,483,822 | 0.37% |
| HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> | 10,032,000 | 0.32% |
| Ducky'S Lifeline Pty Ltd <The R Edwards Super A/C> | 8,826,670 | 0.28% |
| Aubergiste Pty Ltd <Mfc Discretionary A/C> | 8,512,229 | 0.27% |
| Wentworth Williamson Management Pty Ltd | 8,373,970 | 0.27% |
| Mr Mark Shane Aitken | 8,140,000 | 0.26% |